Kirk’s Guardant360® Story with Non-Small Cell Lung Cancer

Kirk and his wife, Jayne, share their story of how Kirk was diagnosed with Stage IV non-small cell lung cancer, worked with his doctor to use Guardant360 to help guide his treatment plan, and have survived (and thrived) for 10 years without having been on chemotherapy.

To learn more:
For patients: https://www.guardantcomplete.com/pati...
For healthcare professionals: https://www.guardantcomplete.com/prod...

Indication Statement(s): Guardant360 is a laboratory developed test that identifies potential tumor-related genomic alterations through analysis of cfDNA that is circulating in blood. Tumor or biopsy sample is not needed to perform this test. Guardant360 can be used in patients with advanced solid-tumor cancers of all types, including but not limited to lung, breast, colorectal, and melanoma. Guardant360 can also be used in situations where biopsy material is not readily available and where obtaining a blood specimen can provide information on genomic alterations in cancer that is not otherwise accessible from a patient. Guardant360 is not intended to be used as the sole means for clinical diagnosis or patient management decisions and should be interpreted in context with other clinical criteria (e.g., patient history, physical exam), as well as laboratory, pathology, and imaging studies by a qualified medical professional.

Copyright © Guardant Health 2024